Right now, the big story, however, is the involvement of mARC1 in liver disease, more specifically in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Here, MTARC1 is linked to metabolic dysfunction-associated steatohepatitis.